title: Imaging [18F]FAU [1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl) uracil] in dogs.
abstract: We have studied the biodistribution of [(18)F]FAU [(1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)uracil], which previous work has shown is incorporated into DNA and functions as an inhibitor of DNA synthesis. It is being tested as a potential antineoplastic agent and imaging agent for PET. We have produced [(18)F]FAU and injected the tracer into 3 normal dogs and imaged them for up to 4 hours and removed tissues along with blood and urine samples for HPLC and activity analysis. The results showed that [(18)F]FAU evenly distributed to most of organs. In sharp contrast to our prior experience with thymidine and its analogs, marrow had less retention of [(18)F]FAU than the non-proliferating tissues.
authors.affiliation: Karmanos Cancer Institute, Department of Medicine, Wayne State University, Detroit Medical Center, Detroit, Michigan, USA.
authors.forename: Haihao
authors.initials: H
authors.lastname: Sun
authors.forename: Jerry M
authors.initials: JM
authors.lastname: Collins
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Mangner
authors.forename: Otto
authors.initials: O
authors.lastname: Muzik
authors.forename: Anthony F
authors.initials: AF
authors.lastname: Shields
mesh_terms: D000818:Animals; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D004273:DNA, Neoplasm / Q000378:metabolism; D004285:Dogs; D005462:Fluorine Radioisotopes / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D009928:Organ Specificity; D019275:Radiopharmaceuticals / Q000097:blood / Q000138:chemical synthesis / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed / Q000379:methods; D014915:Whole-Body Counting
chemical_list: C457880:2'-fluorodeoxyuracil-arabinofuranoside; D004273:DNA, Neoplasm; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D001086:Arabinofuranosyluracil